

Mikio Sugimoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2043929/publications.pdf>

Version: 2024-02-01

74
papers

657
citations

687363

13
h-index

713466

21
g-index

81
all docs

81
docs citations

81
times ranked

981
citing authors

#	ARTICLE	IF	CITATIONS
1	Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 666-671.	3.9	4
2	Incidental Bladder Cancer Found on Cystoscopy during Prostate Biopsy: Prevalence, Pathological Findings, and Oncological Outcome. <i>Urologia Internationalis</i> , 2022, 106, 791-797.	1.3	1
3	Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 107.e1-107.e9.	1.6	1
4	A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 187-196.	1.3	3
5	Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 194-201.	2.2	4
6	Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden. <i>International Journal of Urology</i> , 2022, , .	1.0	4
7	Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy. <i>JNCI Cancer Spectrum</i> , 2022, 6, pkac001.	2.9	3
8	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. <i>European Urology Open Science</i> , 2022, 35, 59-67.	0.4	13
9	Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 441-448.	1.3	9
10	Impact of the severity of urethrovesical anastomotic leakage on urinary continence following robot-assisted laparoscopic prostatectomy. <i>Journal of Robotic Surgery</i> , 2022, 16, 1175-1181.	1.8	1
11	Editorial Comment from Dr Taoka and Dr Sugimoto to Substratification of patients with highest-risk non-muscle invasive bladder cancer helps to identify the candidates for immediate radical cystectomy: A two-center study. <i>International Journal of Urology</i> , 2022, 29, 936-937.	1.0	0
12	Successful establishment of crowdfunding to develop new diagnostic tools for chronic prostatitis. <i>International Journal of Urology</i> , 2022, 29, 600-602.	1.0	1
13	Narrative review of local prostate and metastasis-directed radiotherapy in the treatment of metastatic prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 633-641.	1.3	2
14	The Paris System for reporting urinary cytology improves the negative predictive value of high-grade urothelial carcinoma. <i>BMC Urology</i> , 2022, 22, 51.	1.4	7
15	Photodynamic diagnosis-assisted transurethral resection using oral 5-aminolevulinic acid decreases residual cancer and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 38, 102838.	2.6	11
16	Low quality of life in men with chronic prostatitis-like symptoms. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 785-790.	3.9	5
17	Editorial Comment from Dr Taoka and Dr Sugimoto to <sc>Real-world</sc> treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guérin treatment. <i>International Journal of Urology</i> , 2022, 29, 1130-1130.	1.0	0
18	Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN. <i>World Journal of Urology</i> , 2021, 39, 2491-2497.	2.2	9

#	ARTICLE	IF	CITATIONS
19	The Impact of Histopathological Features of Prostate Cancerous Lesions on Multiparametric Magnetic Resonance Imaging Findings using PI-RADS Version 2. <i>Urology</i> , 2021, 149, 174-180.	1.0	1
20	Significance of the timing of ureteral ligation on prognosis during radical nephroureterectomy for upper urinary tract urothelial cancer. <i>International Journal of Urology</i> , 2021, 28, 208-214.	1.0	4
21	The predictive factor for pathological downgrading after prostatectomy in patients with biopsy Gleason score 4+3 or 4+4 prostate cancer. <i>Molecular and Clinical Oncology</i> , 2021, 14, 56.	1.0	4
22	External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 810-818.	1.3	0
23	Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. <i>Cancer Science</i> , 2021, 112, 1524-1533.	3.9	19
24	Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. <i>International Journal of Urology</i> , 2021, 28, 727-732.	1.0	11
25	Efficacy and toxicity of intravesical Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer. <i>Current Urology</i> , 2021, 15, 16-21.	0.6	5
26	Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4102.	4.1	5
27	6p.21 translocation renal cell carcinoma in the elderly: radiological findings mimicking fat poor angiomyolipoma or papillary renal cell carcinoma. <i>International Cancer Conference Journal</i> , 2021, 10, 233-238.	0.5	2
28	Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. <i>Journal of Geriatric Oncology</i> , 2021, 12, 834-837.	1.0	1
29	Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 56.e9-56.e9.	1.6	2
30	Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. <i>Cancer Science</i> , 2021, 112, 3616-3626.	3.9	8
31	Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2104-2112.	2.2	3
32	Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: A literature review. <i>International Journal of Urology</i> , 2021, 28, 1086-1092.	1.0	17
33	Positive Culture Prior to Transperineal Prostate Biopsy Was Not Associated with Post-Biopsy Febrile Urinary Tract Infection Development. <i>Research and Reports in Urology</i> , 2021, Volume 13, 691-698.	1.0	3
34	Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 508.	0.8	10
35	Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. <i>European Urology Open Science</i> , 2021, 34, 47-54.	0.4	3
36	Transplant Prognosis in Kidney Transplant Recipients with Diabetes under Mycophenolic Acid-Focused Therapeutic Drug Monitoring. <i>Journal of Personalized Medicine</i> , 2021, 11, 1224.	2.5	0

#	ARTICLE	IF	CITATIONS
37	Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged "no-problems". <i>Quality of Life Research</i> , 2020, 29, 755-763.	3.1	2
38	Spontaneous lumbar artery rupture in a kidney transplant patient: A case report. <i>Urology Case Reports</i> , 2020, 29, 101092.	0.3	0
39	Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401). <i>European Urology</i> , 2020, 77, 689-698.	1.9	17
40	Impact of second transurethral resection on recurrence in patients with high-grade Ta bladder cancer. <i>International Journal of Urology</i> , 2020, 27, 1130-1135.	1.0	8
41	Spontaneous rupture of a hybrid oncocytic chromophobe tumor: A case report. <i>Urology Case Reports</i> , 2020, 33, 101304.	0.3	0
42	Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer. <i>BJUI Compass</i> , 2020, 1, 165-173.	1.3	11
43	The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 2107-2114.	2.2	10
44	Quality of life in active surveillance for early prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 296-306.	1.0	9
45	Hyperthermic therapy using warm sterile water enhances cytotoxic effects on bladder cancer cells. <i>Scandinavian Journal of Urology</i> , 2020, 54, 65-69.	1.0	2
46	Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 2460-2471.	3.9	7
47	TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer. <i>PLoS ONE</i> , 2019, 14, e0220173.	2.5	6
48	Particle therapy for prostate cancer: The past, present and future. <i>International Journal of Urology</i> , 2019, 26, 971-979.	1.0	28
49	Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 766-771.	1.3	6
50	Body Fat Area as a Predictive Marker of New-Onset Diabetes Mellitus After Kidney Transplantation. <i>Transplantation Proceedings</i> , 2019, 51, 3281-3285.	0.6	2
51	A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis. <i>BMC Urology</i> , 2019, 19, 99.	1.4	11
52	Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P. <i>Quality of Life Research</i> , 2019, 28, 2383-2391.	3.1	10
53	The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients. <i>BMC Cancer</i> , 2019, 19, 156.	2.6	13
54	Genital elephantiasis possibly caused by chronic inguinal eczema with streptococcal infection. <i>Journal of Dermatology</i> , 2019, 46, e196-e198.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2019, 202, 1127-1135.	0.4	13
56	A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study. <i>BMC Cancer</i> , 2018, 18, 290.	2.6	1
57	A case of retroperitoneal vascular malformation. <i>Urology Case Reports</i> , 2018, 21, 75-77.	0.3	2
58	Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 732-740.	1.6	14
59	Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A. <i>World Journal of Urology</i> , 2017, 35, 1737-1744.	2.2	20
60	Evidence-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association). <i>Urology</i> , 2017, 90, 1111-1115.	1.0	111
61	A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. <i>International Journal of Clinical Oncology</i> , 2017, 22, 166-173.	2.2	45
62	Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study). <i>International Journal of Clinical Oncology</i> , 2016, 21, 1142-1149.	2.2	0
63	Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples. <i>PLoS ONE</i> , 2016, 11, e0165109.	2.5	18
64	Uncommon gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: A report of four cases. <i>Oncology Letters</i> , 2015, 10, 2895-2898.	1.8	8
65	Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 867-873.	1.3	17
66	Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells. <i>Oncology Reports</i> , 2015, 33, 566-572.	2.6	10
67	Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience. <i>Japanese Journal of Clinical Oncology</i> , 2015, 46, 180-187.	1.3	12
68	Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN. <i>World Journal of Urology</i> , 2015, 33, 981-987.	2.2	13
69	The Phytotherapeutic Agent, Eviprostat, Suppresses Stromal Proliferation and Inflammation Even After Establishment of Nonbacterial Prostatitis in the Rat Prostate. <i>Urology</i> , 2014, 83, 528-534.	1.0	7
70	Repeat biopsy outcomes and change in QOL status at 1 year after active surveillance: Results from a Japanese multicenter prospective study and the PRIAS-JAPAN. <i>Journal of Clinical Oncology</i> , 2012, 30, e15127-e15127.	1.6	0
71	Effect of the Phytotherapeutic Agent Eviprostat on Inflammatory Changes and Cytokine Production in a Rat Model of Nonbacterial Prostatitis. <i>Urology</i> , 2011, 77, 1507.e15-1507.e20.	1.0	17
72	Effect of a phytotherapeutic agent, Eviprostat®, on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitis. <i>Prostate</i> , 2011, 71, 438-444.	2.3	21

#	ARTICLE	IF	CITATIONS
73	Influence of Inflammation and Aging on Macrophage Inhibitory Cytokine-1 Gene Expression in Rat Ventral Prostate. <i>Urology</i> , 2009, 73, 410-414.	1.0	7
74	Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN study. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	1.3	3